EUVIMEDEUVIMED entdecken
VergleichsstudieSystematische Übersicht

Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain

Sonia Santos-Lasaosa, Beatriz Armada, Carlota Moya-Alarcón, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Pablo Irimia

Expert Review of Pharmacoeconomics & Outcomes Research · 16.03.2026 · 26 (3) · 361-368

DOI: 10.1080/14737167.2026.2615680 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 12.01.2026. Verfasst von Sonia Santos-Lasaosa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Hospital Clínico Universitario Lozano Blesa, Universidad de Zaragoza, Zaragoza, Spain. Hauptthemen laut MEDLINE: Migraine Disorders, Piperidines, Pyridines, Benzamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To compare the cost of adverse events (AEs) associated with the acute treatment with rimegepant (RIM) versus lasmiditan (LAS) for migraine in Spain. METHODS: A probabilistic modeling analysis was performed, using second-order Monte Carlo simulations, from the perspective of the Spanish National Health System (SNHS). The cost per patient of all AEs described with RIM or LAS in 12 clinical trials, obtained through a systematic review, was analyzed. Several sensitivity analyzes (among them, a matching adjusted indirect comparison -MAIC- of the two long-term studies) were also performed. The cost of AEs management (€ 2024) was obtained from Spanish sources. RESULTS: The probabilistic model estimated that RIM compared to LAS would generate savings of €612.79 (95% CI €159.49-1339.43) per treated patient with migraine, in a treatment period of 6.11 ± 3.25 months, €98.54 per month. In the MAIC analysis, a saving per patient of €697.04 (95% CI: €514.44-879.04) was obtained in a treatment period of 12.4 months. The probability of RIM saving in all analysis was 100%. CONCLUSIONS: In accordance with this model, the favorable safety profile of RIM compared to LAS would generate savings for the SNHS in health-care resources in all the scenarios considered. According to a probabilistic model based on the analysis of clinical trials that examined all AEs observed in patients receiving acute treatment with RIM and LAS, the favorable safety profile of RIM compared to LAS would generate savings for the Spanish NHS in healthcare resources in all the scenarios considered. These savings per patient would range from approximately €612 to €697, depending on the type of analysis performed. The maximum savings per patient would be approximately €752.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersPiperidinesPyridinesBenzamidesSpainHumansMonte Carlo MethodModels, StatisticalCost SavingsTime FactorsDrug CostsModels, Economic

Stichwörter der Autor:innen

CGRP antagonistGepantsacute treatmentadverse effectscost savingsditanshealth-care resourcesmigraine

Substanzen

PiperidinesPyridineslasmiditanBenzamides

Autor:innen und Institutionen

  • Neurology Department, Hospital Clínico Universitario Lozano Blesa, Universidad de Zaragoza, Zaragoza, Spain.
  • Neuroscience Department, Aragon Institute for Health Research (IIS Aragón), Zaragoza, Spain.
  • Medical Department, Pfizer, S.L.U, Madrid, Spain.
  • Health & Value Department, Pfizer, S.L.U, Madrid, Spain.
  • Health Economics Department, Health Value, S.L., Madrid, Spain.
  • Neurology and Neurosurgery Department, Clínica Universidad de Navarra, Pamplona, Spain.

Förderung

  • Pfizer

Zitieren

APA

Santos-Lasaosa, S., Armada, B., Moya-Alarcón, C., Rubio-Rodríguez, D., Rubio-Terrés, C., & Irimia, P. (2026). Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain. Expert Review of Pharmacoeconomics & Outcomes Research, 26(3), 361-368. https://doi.org/10.1080/14737167.2026.2615680

Vancouver

Santos-Lasaosa S, Armada B, Moya-Alarcón C, Rubio-Rodríguez D, Rubio-Terrés C, Irimia P. Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(3):361-368. doi:10.1080/14737167.2026.2615680

BibTeX
@article{SantosLasaosa2026,
  author = {Santos-Lasaosa, Sonia and Armada, Beatriz and Moya-Alarcón, Carlota and Rubio-Rodríguez, Darío and Rubio-Terrés, Carlos and Irimia, Pablo},
  title = {Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {3},
  pages = {361--368},
  doi = {10.1080/14737167.2026.2615680}
}
Kostenlos starten →